Elevated levels of CPL has been described in studies on thyroid cancer [20], melanoma [21], lymphoma [22], kidney and urinary tract cancer [23], gastrointestinal cancer [24], cervical cancer [9,25], uterine cancer [9,26] and nasopharyngeal carcinoma [8]. This evidence concerns the gene HEPH and thyroid gland carcinoma.